^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Dendritic cell renal cell carcinoma fusion vaccine

    i
    Other names: Dendritic cell renal cell carcinoma fusion vaccine, DC/RCC
    Associations

    News

    Trials
    Company:
    Beth Israel Deaconess Medical Center
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    7ms
    Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF (clinicaltrials.gov)
    P1/2, N=38, Completed, Beth Israel Deaconess Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    CSF2 (Colony stimulating factor 2)
    |
    Dendritic cell renal cell carcinoma fusion vaccine
    almost2years
    Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Dec 2022 --> Jul 2023
    Trial completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    Dendritic cell renal cell carcinoma fusion vaccine
    almost3years
    Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Dec 2021 --> Dec 2022
    Trial completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    Dendritic cell renal cell carcinoma fusion vaccine
    over3years
    Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Dec 2020 --> Dec 2021
    Clinical • Trial completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    Dendritic cell renal cell carcinoma fusion vaccine
    almost5years
    Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Beth Israel Deaconess Medical Center | Trial completion date: Dec 2019 --> Dec 2020
    Clinical • Trial completion date
    |
    CSF2 (Colony stimulating factor 2)
    |
    Dendritic cell renal cell carcinoma fusion vaccine